Jazz Pharmaceuticals Plc - 10-Q Summary (Q3 2009)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2009. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neurology and psychiatry. Its primary marketed products are Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for obsessive compulsive disorder and social anxiety disorder. The company is also developing JZP-6 (sodium oxybate) for fibromyalgia, with a New Drug Application (NDA) planned for submission by the end of 2009.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 |
|---|---|---|
| Total Revenues | $30,809 | $90,165 |
| Net Loss | $(1,672) | $(12,489) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.42) |
| Cash and Cash Equivalents (Sep 30, 2009) | $12,230 | N/A |
| Senior Secured Notes Outstanding | $115,363 | N/A |
| Line of Credit Borrowed | $3,000 | N/A |
Revenue Breakdown (Nine Months 2009): Product sales were $77.79 million (Xyrem: $65.12M; Luvox CR: $12.67M). Contract revenues were $10.85 million, driven by a $10.0 million milestone payment from UCB Pharma recognized upon completion of a Phase III trial.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 73% for the three months and 88% for the nine months compared to 2008. This was primarily due to a 76% increase in Xyrem sales (driven by price increases and volume growth) and the launch of Luvox CR.
- Profitability Improvement: The company reported an operating income of $3.71 million for the quarter, a significant turnaround from an operating loss of $27.74 million in the same period in 2008. Net loss narrowed significantly from $28.81 million (Q3 2008) to $1.67 million (Q3 2009).
- Expense Reduction: Operating expenses decreased substantially due to cost-cutting measures, including reductions in force in 2008. R&D expenses dropped 37% (quarterly) and 45% (year-to-date), and SG&A expenses dropped 38% (quarterly) and 53% (year-to-date).
- Debt Status: The company previously defaulted on interest payments on its Senior Secured Notes. In July 2009, it paid $14.6 million in accrued interest and made the September 2009 payment of $4.5 million. Management believes material defaults have been cured.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: As of September 30, 2009, cash and cash equivalents were $12.2 million. Management believes it can fund operations for at least the next 12 months based on cost reductions and increased cash flows. However, the company has a history of net losses, and the auditor's report for 2008 raised substantial doubt about the company's ability to continue as a going concern.
- Debt Risks: The company holds $119.5 million in Senior Secured Notes. While management believes defaults are cured, noteholders could still attempt to accelerate repayment. The company does not have sufficient cash to pay the principal if accelerated.
- Regulatory and Product Risks:
- JZP-6: Approval for fibromyalgia is uncertain. If approved, a Risk Evaluation and Mitigation Strategy (REMS) similar to Xyrem may be required, which could limit market access.
- Luvox CR: Generic competition is imminent. The company received Paragraph IV certifications from Actavis and Anchen regarding generic versions. The company has filed lawsuits in response.
- Xyrem: Orphan drug exclusivity for cataplexy expired in July 2009, though exclusivity for excessive daytime sleepiness remains until November 2012.
- Unusual Items: The $10.0 million contract revenue recognized in the nine months ended September 30, 2009, was a non-cash milestone payment received previously from UCB. Additionally, the company recorded a $5.0 million increase in intangible assets related to the Luvox CR license agreement amendment.
Investor Verification Checklist
- Debt Acceleration Risk: Verify the status of the Senior Secured Notes and whether noteholders have formally waived the right to accelerate repayment following the cure of defaults.
- Cash Runway: Confirm current cash balances and burn rate to validate the 12-month liquidity projection, especially given the history of net losses.
- Generic Competition: Monitor the status of the lawsuits against Actavis and Anchen regarding Luvox CR and the potential impact on future revenue.
- JZP-6 NDA Submission: Track the timeline for the submission of the New Drug Application for JZP-6 and the FDA's review process.
- Customer Concentration: Note that five largest customers accounted for approximately 97% of gross accounts receivable, with Express Scripts representing 81% of total revenues in Q3 2009.